Table 3.
Frequency of concomitant medications taken for co-occurring medical and psychiatric problems among 350 cigarette smoking patients at community-based substance abuse treatment programs. *
| Conditions for which medications were taken | Number of Patients | Percent |
|---|---|---|
| Any Medical Condition | 296 | 84.6% |
| Pain | 122 | 37.7% |
| Cardiac and Vascular Disorders | 80 | 24.7% |
| Respiratory | 74 | 22.8% |
| Sleep | 73 | 22.5% |
| Cold and Allergy | 61 | 18.8% |
| Supplements | 50 | 15.4% |
| GI | 47 | 14.5% |
| Infections and Infestations | 46 | 14.2% |
| Metabolic | 39 | 12.0 % |
| Musculoskeletal | 34 | 10.5% |
| HIV/Aids | 25 | 7.7% |
| Reproductive | 19 | 5.9% |
| Nervous System | 18 | 5.6% |
| Skin | 15 | 4.6% |
| Surgical or Procedures | 10 | 3.1% |
| Blood and Lymphatic System Disorders | 9 | 2.8% |
| Renal | 4 | 1.2% |
| Eye Disorders | 4 | 1.2% |
| Ear and Labyrinth Disorders | 2 | 0.6% |
| Any Psychiatric Condition | 160 | 49.3% |
| Major Depression | 126 | 38.9% |
| Anxiety and Panic Disorders | 63 | 19.4% |
| Bi Polar Disorder | 29 | 8.6% |
| ADHD | 7 | 2.2% |
| Schizophrenia | 10 | 3.1% |
| Unspecified psychosis | 20 | 6.2% |
| Multiple psychiatric indications | 16 | 4.9% |
*
Participants were examined by a physician as part of the evaluation prior to enrollment in a clinical trial of a smoking cessation intervention. Values in the table are number and percent of patients reporting medications for problems in each category.